Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.

Hamidieh AA, Alimoghaddam K, Jahani M, Bahar B, Mousavi SA, Iravani M, Behfar M, Jalali A, Jalili M, Hamdi A, Ghavamzadeh A.

J Pediatr Hematol Oncol. 2013 Aug;35(6):e239-45. doi: 10.1097/MPH.0b013e31827080fc. Erratum in: J Pediatr Hematol Oncol. 2014 Apr;36(3):252.

PMID:
23042019
2.

[Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].

Wang HH, Feng SZ, Wang M, Wei JL, Jiang EL, Zhang L, Huang Y, Zhou SY, Liu QG, Qiu LG, Han MZ, Yan WW.

Zhonghua Xue Ye Xue Za Zhi. 2004 Jul;25(7):389-92. Chinese.

PMID:
15355688
3.

Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.

Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim NH, Jang MK, Kim H, Song SH, Park JD, Park KD, Shin HY, Jang IJ, Ahn HS.

Biol Blood Marrow Transplant. 2015 Jan;21(1):190-5. doi: 10.1016/j.bbmt.2014.09.013. Epub 2014 Sep 22.

4.

Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.

Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, Goto H, Inagaki J, Koh K, Terui K, Ogawa A, Kawano Y, Inoue M, Sawada A, Kato K, Atsuta Y, Yamashita T, Adachi S.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10.

5.

Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.

Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor DS, Frangoul HA.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1620-7. doi: 10.1016/j.bbmt.2009.08.014. Epub 2009 Oct 1.

6.

[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].

Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.

Zhonghua Nei Ke Za Zhi. 2012 Nov;51(11):880-4. Chinese.

PMID:
23291027
8.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

9.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.

Bone Marrow Transplant. 2000 Oct;26(7):711-6.

10.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
11.

Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.

Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C, Yaniv I, Fagioli F, Castel V, Shaw PJ, Ferrant A, Pession A, Sociè G, Frassoni F; European Blood and Marrow Transplantation Acute Leukemia Working Party.

Blood. 2003 Feb 15;101(4):1611-9. Epub 2002 Oct 10.

12.
13.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

14.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.

Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K; Lymphoma Working Committee of the International Bone Marrow Transplant Registry.

Blood. 2004 Dec 1;104(12):3797-803. Epub 2004 Jul 27.

16.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

17.

Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.

Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE.

Biol Blood Marrow Transplant. 2003 Nov;9(11):706-13.

18.

The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.

Hamidieh A, Kargar M, Jahani M, Alimoghaddam K, Bahar B, Mousavi SA, Iravani M, Jalali A, Jalili M, Ghavamzadeh A.

J Pediatr Hematol Oncol. 2012 Mar;34(2):101-7. doi: 10.1097/MPH.0b013e31824435a1.

PMID:
22367385
19.

[Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].

Liu QF, Sun J, Xu D, Zhang Y, Fan ZP, Wei YQ, Meng FY, Zhou SY.

Di Yi Jun Yi Da Xue Xue Bao. 2004 Oct;24(10):1117-9. Chinese.

20.

Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.

Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.

Biol Blood Marrow Transplant. 2010 Jun;16(6):818-23. doi: 10.1016/j.bbmt.2010.01.002. Epub 2010 Jan 14.

Supplemental Content

Support Center